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Abstract 
Background: The role of vitamin D status in COVID-19 patients is a matter of debate.
Objectives: To assess serum 25-hydroxyvitamin D (25OHD) levels in hospitalized patients 
with COVID-19 and to analyze the possible influence of vitamin D status on disease 
severity.
Methods: Retrospective case–control study of 216 COVID-19 patients and 197 population-
based controls. Serum 25OHD levels were measured in both groups. The association 
of serum 25OHD levels with COVID-19 severity (admission to the intensive care unit, 
requirements for mechanical ventilation, or mortality) was also evaluated.
Results: Of the 216 patients, 19 were on vitamin D supplements and were analyzed 
separately. In COVID-19 patients, mean ± standard deviation 25OHD levels were 
13.8 ± 7.2 ng/mL, compared with 20.9 ± 7.4 ng/mL in controls (P < .0001). 25OHD values 
were lower in men than in women. Vitamin D deficiency was found in 82.2% of COVID-
19 cases and 47.2% of population-based controls (P < .0001). 25OHD inversely correlates 
with serum ferritin (P = .013) and D-dimer levels (P = .027). Vitamin D-deficient COVID-19 
patients had a greater prevalence of hypertension and cardiovascular diseases, raised 
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serum ferritin and troponin levels, as well as a longer length of hospital stay than those 
with serum 25OHD levels ≥20 ng/mL. No causal relationship was found between vitamin D 
deficiency and COVID-19 severity as a combined endpoint or as its separate components.
Conclusions: 25OHD levels are lower in hospitalized COVID-19 patients than in 
population-based controls and these patients had a higher prevalence of deficiency. We 
did not find any relationship between vitamin D concentrations or vitamin deficiency and 
the severity of the disease.
Freeform/Key Words:  25OHD, PTH, SARS-CoV-2 infection, COVID-19
There are several lines of evidence that might support a 
role for vitamin D status in SARS-CoV-2 infection. Firstly, 
vitamin D deficiency is a common condition all around 
the world, and serum 25-hydroxyvitamin D (25OHD) 
levels follow a well-known seasonal and geographical pat-
tern. Spain, located in temperate zones of the Northern 
Hemisphere, but with a higher prevalence of vitamin D 
deficiency (1), has reached very high rates of SARS-CoV-2 
infection and lethality (2). Secondly, vitamin D is a steroid 
hormone involved in the modulation of the innate and 
acquired immune system and also in the production of 
antimicrobial peptides, such as cathelicidin and human 
β-defensin-2, as well as in the expression of genes involved 
in the intracellular destruction of pathogens (3-5). Thirdly, 
low serum 25OHD levels are frequently found in elderly 
individuals or in those with chronic conditions, such as 
hypertension, diabetes, cancer, or cardiovascular diseases, 
which have also been reported as poor prognostic factors 
for COVID-19 (6-11). Finally, the downregulation of ACE2 
by SARS-CoV-2 leads to a dysregulation of the renin–angio-
tensin system (RAS), which contributes to the “cytokine 
storm” that precedes the acute respiratory distress syn-
drome (ARDS) characteristic of the severe form of COVID-
19. In this sense, vitamin D can inhibit proinflammatory 
cytokine production in human monocytes/macrophages 
(12), and chronic vitamin D deficiency may induce RAS ac-
tivation, leading to the production of fibrotic factors and, 
therefore, lung damage (13).
Taking into account the above considerations, we aimed 
to assess the serum 25OHD levels in hospitalized patients 
with COVID-19 compared with population-based controls. 
The possible association between serum 25OHD concen-
trations and COVID-19 severity and mortality was also 
analyzed.
Patients and Methods
Study design and participants
The study consists of 2 parts. Firstly, we have designed a 
retrospective case–control study including 216 patients 
aged ≥18 years with confirmed COVID-19 admitted to the 
University Hospital Marqués de Valdecilla in Santander, 
northern Spain, from March 10 to March 31, 2020, and 
197 sex-matched population-based controls recruited from 
the Camargo Cohort (14, 15) during their last follow-up 
visit in January to March of the past year. From the present 
study, we have excluded patients or controls with malab-
sorption disorders, liver cirrhosis, serum creatinine levels 
>1.9  mg/dL, or previous treatment with anticonvulsants. 
Nineteen COVID-19 patients on oral vitamin D supple-
ments for more than 3  months at admission were ana-
lyzed as a separate group, and controls who receive these 
supplements were also excluded from the study. Secondly, 
we have assessed only the group of COVID-19 patients to 
evaluate the possible influence of vitamin D deficiency on 
the outcome of the disease. Participants from the Camargo 
Cohort gave their informed written consent and the study 
was approved by the Cantabria Clinical Research Ethics 
Committee (internal code 2016.003). The present study 
was approved by the Ethics Committee of Cantabria (in-
ternal code 2020.55). Serum samples from Covid-19 pa-
tients were provided by the IDIVAL Biobank samples 
collection (internal code 2020-126).
Data collection
Demographic, clinical, and outcome data of COVID-19 
patients were gathered from hospital records, stored in a 
computerized database, and independently reviewed by 2 
researchers. Missing data were not imputed. Smoking status 
was coded as current or nonsmoker. Immunosuppression 
included prolonged use (≥3 months) of corticoids (>10 mg/
day of prednisone or equivalent) or immunomodulatory 
agents, and bone marrow or organ transplantation. Chest 
X-ray and/or computed tomography scans were performed 
in all COVID-19 patients. Concerning immunomodulatory 
therapy, patients were selected for tocilizumab according 
to our institutional protocol. Thus, tocilizumab was indi-
cated if there was clinical worsening with PaO2/FIO2 ratio 
<300 and high serum acute-phase reactant levels when 
no contraindication for its use was present. The endpoint 
variable for COVID-19 severity has been defined as the 
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composite of admission to the intensive care unit (ICU), re-
quirement for mechanical ventilation, or in-hospital mor-
tality. Clinical outcomes were monitored up to May 20, 
2020. Overall, the criteria for ICU admission were those 
of the guidelines by the American Thoracic Society and 
Infectious Diseases Society of America (16) and the critical 
care ethic recommendations for the SARS-CoV-2 pandemic 
by the Intensive Medicine Spanish Society (17). ARDS was 
the main cause of ICU admission and a case-by-case as-
sessment was carried out by the medical COVID team, 
including intensivists.
Laboratory measurements
Qualitative detection of RNA from the SARS-CoV-2 was 
performed by using real-time polymerase chain reaction. 
Blood samples from the controls were obtained from an 
antecubital vein in the morning after a requested 12-hour 
overnight fast. The serum was divided into 0.5-mL aliquots 
and stored at –40°C. Routine biochemical parameters were 
measured by standard automated methods in a Technicon 
Dax autoanalyzer (Technicon Instruments, CO, USA). 
Human interleukin (IL)-6 was measured by enzyme-linked 
immunosorbent assay (Enzo Life Sciences, Inc. Farmingdale, 
NY) following the manufacturer instructions. The sensi-
tivity for serum IL-6 levels was 0.057  pg/mL. Intra- and 
interassay precision was 4.38% and 9.6%, respectively. 
Serum 25OHD concentrations were determined in controls 
by a fully automated electrochemiluminescence system 
(Elecsys 2010, Roche Diagnostics, GmbH, Mannheim, 
Germany). The detection limit of serum 25OHD was 4 ng/
mL. The intra-assay coefficient of variation (CV) was 5% 
and interassay was 7.5%. In COVID-19 patients, serum 
25OHD levels were obtained at admission and assessed by 
automated competitive chemiluminescence assay (Liaison 
XL, DiaSorin Inc, Stillwater MN, USA). Our laboratory is 
DEQAS (Vitamin D External Quality Assessment Scheme) 
certified for this parameter. The detection limit of serum 
25OHD was 4 ng/mL. The intra-assay and interassay CV 
were 2.58% and 7.83%, respectively. We have previously 
found a correlation between both techniques of 0.926 
(P < .0001) with a random sample of 52 subjects from the 
Camargo Cohort.
Statistical analysis
Continuous variables were expressed as mean ± standard de-
viation (SD) or median and interquartile range and compared 
with the Student’s t-test or Mann–Whitney U test according to 
the distribution of data. Categorical variables were presented 
as numbers and percentages and compared using the chi-
squared test or the Fisher exact test as appropriate. Spearman 
rho was used to assess the relationships between serum 
25OHD levels and several clinical and laboratory param-
eters. Serum 25OHD levels were stratified into 4 categories: 
below 10  ng/mL, between 10 and 20  ng/mL, between 20 
and 30 ng/mL, and above 30 ng/mL. Vitamin D deficiency 
was defined as serum 25OHD levels <20 ng/mL (50 nmol/L) 
following a recent position paper by the European Calcified 
Tissue Society Working Group (18). A multivariable general 
linear model was set up to compare serum 25OHD levels 
between COVID-19 patients and controls (Bonferroni test), 
adjusting for confounding variables. In the group of COVID-
19 patients, univariable and multivariable binary logistic re-
gression analyses were used to assess the association between 
vitamin D (as a continuous variable, or expressed as vitamin 
D deficiency or as quintiles) and the dependent variable of se-
verity of the disease. A 2-sided P-value less than .05 was con-
sidered statistically significant in all the calculations. A post 
hoc power analysis with the present sample size and the 
obtained difference in serum 25OHD levels between cases 
and controls yields a power of 100% to detect this difference. 
In fact, a difference of 2.1  ng/mL between groups already 
yields a potency of 89.8%. Nevertheless, due to the sample 
size and the lower number of events (especially mortality) in 
COVID-19 patients with and without vitamin D deficiency, 
the post hoc power analysis for the severity endpoints was 
lower than 40%.
Results
We included 216 adult COVID-19 patients, of whom 19 
were on vitamin D supplementation (11 patients were 
taking cholecalciferol, 25 000 IU/monthly in 10 cases, and 
5600 IU/weekly in 1, and 8 patients were on calcifediol, 
0.266  mg/monthly). The main demographic, epidemio-
logical, and clinical characteristics of the 3 groups included 
in the study are summarized in Table 1. COVID-19 patients 
on vitamin D supplements were mainly women and had 
a greater prevalence of hypertension and immunosuppres-
sion than the other 2 groups analyzed. Population-based 
controls included more smokers and had a lower glom-
erular filtration rate and greater serum parathormone levels 
than COVID-19 patients.
Table 2 summarizes the demographic, clinical, and la-
boratory data of COVID-19 patients (excluding those on 
vitamin supplements) according to the presence of vitamin 
D deficiency (serum 25OHD levels <20  ng/mL. Vitamin 
D-deficient COVID-19 patients had a greater prevalence of 
hypertension and cardiovascular diseases, raised serum fer-
ritin and troponin levels, as well as a longer length of hos-
pital stay than those with serum 25OHD levels ≥20 ng/mL.
The features of COVID-19 patients according to the ac-
tive use of vitamin D supplements are shown in Table  3. 
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Patients on supplements had a significantly lower PaO2/FIO2 
ratio <300 prevalence, lower serum ferritin levels, and re-
ceived less frequently tocilizumab than COVID-19 patients 
who did not take vitamin D supplements. They also had an 
overall lower percentage of the combined severity endpoint 
and ICU admissions, as well as a shorter length of hospital 
stay, although these data did not reach statistical significance.
Furthermore, when we pooled together patients with 
25OHD levels ≥20 ng/mL (both at basal levels and with 
vitamin D supplements) and compared with patients with 
vitamin D deficiency, those with higher levels had a slightly 
better outcome expressed as a lower PaO2/FIO2 ratio <300 
(12.8% vs. 27.8%; P = .034), lower requirements for 
tocilizumab (17% vs. 33.1%; P = .032), less frequent radio-
logical progression (14.9% vs. 30.2%; P = .037), lower 
ICU admissions (12.8% vs. 26.6%; P = .048), and also a 
shorter hospital stay (12.0 [8.0-17.0] vs. 8.0 [6.0-14.0] 
days; P = .002). No difference was found regarding the 
composite severity endpoint (21.3% vs. 30.8%; P = .203) 
nor mortality (12.9% vs. 9.8%; P = .590).
In COVID-19 patients, mean ± SD 25OHD levels were 
13.8 ± 7.2 ng/mL, compared with 20.9 ± 7.4 ng/mL in controls 
(P < .0001). The distribution of serum 25OHD levels in hos-
pitalized COVID-19 patients with or without vitamin D sup-
plements and controls, grouped by gender, is shown in Fig. 1. 
Serum 25OHD values were lower in men than in women. 
Fig.  2 shows the percentage of COVID-19 cases (without 
vitamin D supplementation) and controls within the different 
intervals of serum 25OHD levels. Vitamin D deficiency was 
found in 82.2% of COVID-19 cases and 47.2% of population-
based controls (P < .0001). 25OHD inversely and significantly 
correlated with serum ferritin and D-dimer, and there was a 
trend with C-reactive protein levels (Fig. 3). We did not find 
any statistical relationship between serum vitamin D and IL-6 
levels in patients with COVID-19 (rho –0.032; P = .67), al-
though levels of this cytokine were lower, albeit nonsignificant, 
in patients with serum vitamin D levels ≥20 ng/mL and those 
on vitamin D supplements (Table 3).
In the multivariable general linear model, mean serum 
25OHD levels were significantly lower in COVID-19 pa-
tients (excluding those on vitamin D supplements) than in 
population-based controls after adjusting for age, smoking, 
hypertension, diabetes mellitus, history of cardiovascular 
events, immunosuppression, body mass index, serum cor-
rected calcium, glomerular filtration rate, and the month of 
vitamin D determination: 11.9 (95% CI 9.6-14.3) ng/mL 
versus 21.2 (95% CI 19.7-22.7) ng/mL (P < .0001).
In COVID-19 patients (once those on vitamin D sup-
plements at admission had been excluded), no relationship 
was found between serum vitamin D levels (as a continuous 
variable or expressed as vitamin D deficiency or as quin-
tiles), and the composite severity endpoint or its separate 
components, in crude or adjusted logistic regression models 
(combine severity endpoint: unadjusted OR 1.55, 95% CI 
0.66-3.65; P = .315; adjusted OR 1.13, 95% CI 0.27-4.77; 
P = .865; for vitamin D deficiency).








Age (years), median (IQR) 61.0 (47.5-70.0) 60.0 (59.0-75.0) 61.0 (56.0-66.0) .082 .153 .182
Sex (male), n (%) 123 (62.4) 7 (36.8) 123 (62.4) .030 .999 .030
BMI (kg/m2), mean ± SD 29.2 ± 4.7 30.9 ± 6.3 28.9 ± 4.0 .134 .557 .035
Current smoker, n (%) 14 (7.1)  2 (10.5) 34 (17.3) .638 .002 .747
Hypertension, n (%) 76 (38.6) 12 (63.2) 87 (44.2) .037 .260 .113
Diabetes, n (%) 34 (17.3) 0 (0.0) 31 (15.7) .049 .684 .083
Cardiovascular disease, n (%) 21 (10.7) 3 (15.8) 22 (11.2) .451 .872 .468
COPD, n (%) 15 (7.6) 2 (10.5) 9 (4.6) .650 .206 .250
Active cancer, n (%) 7 (3.6) 0 (0.0) 8 (4.1) .999 .792 .999
Immunosuppression, n (%) 16 (8.1) 6 (31.6) 2 (1.0) .006 .001 <.0001
ACEI / ARA2 agents, n (%) 58 (29.4) 7 (36.8) 47 (23.9) .502 .210 .265
GFR-MDRD-4 (mL/min/1.73 m2), median (IQR) 92.2 (73.9-113.4) 85.9 (69.9-104.9) 71.9 (63.3-91.5) .213 <.0001 .053
C-reactive protein (mg/dl), median (IQR) 5.60 (2.63-11.85) 7.30 (2.90-15.10) 0.25 (0.10-0.50) .756 <.0001 <.0001
Corrected calcium (mg/dL), median (IQR) 8.5 (8.3-9.0) 8.7 (8.4-9.0) 9.1 (8.9-9.3) .175 <.0001 <.0001
25OHD (ng/mL), mean ± SD 13.8 ± 7.2 21.1 ± 5.9 20.9 ± 7.4 <.0001 <.0001 .914
PTH (pg/mL), median (IQR) 42.6 (32.3-62.6) 53.7 (28.8-67.4) 51.6 (42.5-65.2) .389 <.0001 .719
Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; ACEI, angiotensin-converting enzyme inhibitors; ARA2, angiotensin-
receptor 2 antagonists; GFR, glomerular filtration rate; MDRD, modification of diet in renal disease; 25OHD, 25-hydroxyvitamin D; PTH, parathyroid hormone.
aCOVID-19 group vs COVID19_D group.
bCOVID-19 group vs Controls.
cCOVID-19_D group vs Controls.
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Table 2. Main characteristics of COVID-19 patients according to the presence of vitamin D deficiency
Variable 25OHD < 20 ng/mL  
N = 162
25OHD ≥ 20 ng/mL  
N = 35
P
Baseline characteristics    
 Age (years), median (IQR) 62.0 (48.0-70.3) 58.0 (45.0-69.0) .292
 Sex (male), n (%) 106 (65.4) 17 (48.6) .062
 BMI (kg/m2), mean ± SD 29.0 ± 4.9 29.8 ± 4.1 .428
 Current smoker, n (%) 13 (8.0) 1 (2.9) .471
 Hypertension, n (%) 68 (42.0) 8 (22.9) .035
 Diabetes, n (%) 28 (17.3) 6 (17.1) .984
 Cardiovascular disease, n (%) 21 (13.0) 0 (0.0) .029
 COPD, n (%) 13 (8.0) 2 (5.7) .999
 Active cancer, n (%) 7 (4.3) 0 (0.0) .357
 Immunosuppression, n (%) 11 (6.8) 5 (14.3) .169
 ACEI/ARA2 agents, n (%) 52 (32.1) 6 (17.1) .078
Clinical and laboratory data    
 Pneumonia, n (%) 155 (95.7) 33 (94.3) .662
 Respiratory rate >22, n (%) 36 (22.2) 4 (11.4) .150
 CURB-65 score, median (IQR) 1 (1, 2) 1 (1) .229
 SBP < 100 mmHg, n (%) 4 (2.5) 1 (2.9) .999
 PaO2/FIO2 ratio, median (IQR) 444 (424-452) 444 (436-452) .168
 PaO2/FIO2 ratio < 300, n (%) 46 (28.4) 6 (17.1) .171
 Lymphocytes (mm3), median (IQR) 900 (600-1200) 1100 (700-1250) .255
 Neutrophils (mm3), median (IQR) 3900 (2875-6125) 3700 (2900-4600) .207
 Neutrophil/Lymphocyte ratio, median (IQR) 4.85 (3.00-7.52) 3.63 (3.00-6.67) .422
 Platelet count (×109/L), median (IQR) 167 (138-217) 169 (143-211) .833
 D-dimer (ng/mL), median (IQR) 710.5 (469.0-1021.0) 575.0 (434.0-693.0) .057
 Ferritin (ng/mL), median (IQR) 833.0 (330.8-1488.3) 310.0 (137.3-764.0) <.0001
 hs-Troponin I (ng/L), median (IQR) 6.0 (3.0-12.0) 3.0 (3.0-6.0) .015
 C-reactive protein (mg/dL), median (IQR) 6.10 (3.10-13.60) 3.20 (2.30-8.70) .064
 IL-6 (pg/mL), median (IQR) 58.9 (19.1-124.0) 45.6 (20.5-119.0) .63
 GFR-MDRD-4 (mL/min/1.72 m2), median (IQR) 91.4 (73.5-114.7) 98.0 (82.4-113.1) .323
 Corrected calcium (mg/dL), median (IQR) Corrected  
calcium (mg/dl), median (IQR)
8.5 (8.3-9.0) 8.7 (8.4-9.0) .289
 25OHD (ng/mL), mean ± SD 11.2 ± 4.3 25.8 ± 5.6 <.0001
 PTH (pg/mL), median (IQR) 44.2 (32.3-64.8) 35.6 (30.9-46.4) .092
Therapeutic scheme    
 Hydroxychloroquine, n (%) 156 (96.3) 35 (100) .593
 Lopinavir/ritonavir, n (%) 122 (75.3) 31 (88.6) .088
 Azithromycin, n (%) 117 (72.2) 30 (85.7) .096
 Corticosteroids, n (%) 40 (24.7) 7 (20.0) .555
 β-Interferon, n (%) 37 (22.8) 7 (20.0) .715
 Tocilizumab, n (%) 55 (34.0) 8 (22.9) .202
 Anakinra, n (%) 12 (7.4) 1 (2.9) .471
 Noninvasive ventilation, n (%) 12 (7.4) 1 (2.9) .471
Outcome    
 ICU admission, n (%) 44 (27.2) 6 (17.1) .217
 Mechanical ventilationa, n (%) 37 (84.1) 6 (100) .576
 Radiological worsening, n (%) 50 (30.9) 6 (17.1) .103
 Secondary infection, n (%) 38 (23.5) 6 (17.1) .416
 Thrombotic eventsb, n (%) 10 (6.2) 0 (0.0) .214
 Death, n (%) 16 (10.2) 4 (11.4) .765
 Composite severity endpoint, n (%) 111 (68.5) 27 (77.1) .312
 Length of stay (days), median (IQR) 12.0 (8.0-17.0) 8.0 (6.0-14.0) .013
Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; ACEI, angiotensin-converting enzyme inhibitors; ARA2, angiotensin-receptor 2 
antagonists; hs, high-sensitivity; GFR, glomerular filtration rate; MDRD, modification of diet in renal disease; 25OHD, 25-hydroxyvitamin D; PTH, parathyroid hormone.
aRefers only to the number of patients admitted to ICU.
bIncluded pulmonary embolism, deep venous thrombosis, acute coronary syndrome, and cerebrovascular disease. 
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Discussion
We have found that serum 25OHD levels are signifi-
cantly lower in hospitalized COVID-19 patients than in 
population-based controls of similar age and sex, and that 
these differences remain significant even after adjusting for 
the main confounding factors. These levels were especially 
lower in the group of men with COVID-19. Despite the 
high frequency of vitamin D deficiency in patients hos-
pitalized for COVID-19, we did not find an association 
between circulating levels of 25OHD and the severity of 
SARS-CoV-2 infection.
Vitamin D is a hormone with a pleiotropic role and 
there is compelling evidence for an epidemiological 
association between low serum 25OHD levels and human 
infections such as influenza, HIV, and hepatitis C virus 
infection (19). The interplay between vitamin D and viral 
infection is an area of growing interest, and interaction 
with host and viral factors, immunomodulatory effects, 
induction of autophagy and apoptosis, and even genetic 
and epigenetic factors have been reported as antiviral ef-
fects of this hormone (20). In this scenario, the SARS-
CoV-2 virus pandemic has rapidly spread during winter 
with extreme virulence through southern European coun-
tries such as Italy and Spain. Although there was a consid-
erable variation in the prevalence of vitamin D deficiency 
across countries, mainly dependent on age and the use of 
Table 3. Main features in COVID-19 patients with or without oral vitamin D supplements at admission
Variable COVID-19 N = 197 COVID-19_D N = 19 P
Clinical and laboratory data    
 Pneumonia, n (%) 188 (95.4) 18 (94.7) .999
 Respiratory rate >22, n (%) 40 (20.3) 3 (15.8) .772
 CURB-65 score, median (IQR) 1 (1, 2) 1 (1, 2) .353
 SBP < 100 mmHg, n (%) 5 (2.5) 0 (0.0) .999
 PaO2/FIO2 ratio, median (IQR) 444 (428-452) 444 (432-452) .524
 PaO2/FIO2 ratio  < 300, n (%) 52 (26.4) 1 (5.3) .049
 Lymphocytes (mm3), median (IQR) 900 (700-1200) 900 (500-1400) .890
 Neutrophils (mm3), median (IQR) 3900 (2900-5600) 4000 (2200-5100) .624
 Neutrophil/Lymphocyte ratio, median (IQR) 4.75 (3.00-7.38) 4.58 (2.81-7.82) .891
 Platelet count (×109/L), median (IQR) 167 (138-214) 168 (142-236) .478
 D-dimer (ng/mL), median (IQR) 735.5 (254.3-1367.3) 599 (431-1336) .731
 Ferritin (ng/mL), median (IQR) 861 (330-1418) 315 (147.0-743.0) .012
 hs-Troponin I (ng/L), median (IQR) 6.0 (3.5-125.0) 7.0 (3.5-17.0) .979
 C-reactive protein (mg/dl), median (IQR) 5.55 (2.60-11.85) 7.30 (2.90-15.10) .73
 IL-6 (pg/mL), median (IQR) 57.6 (21.6-125.0) 48.8 (13.0-129.8) .80
Therapeutic scheme    
 Hydroxychloroquine, n (%) 191 (97.0) 19 (100) .999
 Lopinavir/ritonavir, n (%) 153 (77.7) 12 (63.2) .164
 Azithromycin, n (%) 147 (74.6) 14 (73.7) .999
 Corticosteroids, n (%) 47 (23.9) 5 (26.3) .783
 β-interferon, n (%) 44 (22.3) 2 (10.5) .378
 Tocilizumab, n (%) 63 (32.0) 1 (5.3) .015
 Anakinra, n (%) 13 (6.6) 1 (5.3) .999
 Non-invasive ventilation, n (%) 13 (6.6) 2 (10.5) .627
Outcome    
 ICU admission, n (%) 50 (25.4) 1 (5.3) .05
 Mechanical ventilationa, n (%) 43 (86.0) 1 (100) .999
 Radiological worsening, n (%) 56 (28.4) 2 (10.5) .093
 Secondary infection, n (%) 44 (22.3) 2 (10.5) .378
 Thrombotic eventsb, n (%) 10 (5.1) 1 (5.3) .999
 Death, n (%) 20 (10.4) 2 (10.5) .999
 Composite severity endpoint, n (%) 59 (29.9) 3 (15.8) .193
 Length of stay (days), median (IQR) 12.0 (8.0-16.0) 8.0 (6.0-14.0) .107
Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; ACEI, angiotensin-converting enzyme inhibitors; ARA2, angiotensin-
receptor 2 antagonists; hs, high-sensitivity; GFR, glomerular filtration rate; MDRD, modification of diet in renal disease; 25OHD, 25-hydroxyvitamin D; PTH, 
parathormone.
aRefers only to the number of patients admitted to ICU.
bIncluded pulmonary embolism, deep venous thrombosis, acute coronary syndrome, and cerebrovascular disease. 
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vitamin D supplements or food fortification, vitamin D 
deficiency (25OHD levels <20  ng/mL) is found in 40% 
of European citizens irrespective of age group, ethnic 
mix, and latitude (18). The population with more se-
vere COVID-19, such as elderly people and patients with 
comorbidities with the highest case fatality rates (21), 
are also those with lower serum 25OHD levels according 
to published data (18). Thus, the Seneca study showed a 
mean 25OHD concentration of 10.4 ng/mL (26 nmol/L) 
in elderly subjects aged 70 to 75  years in Spain (22). 
Recently, Ilie et  al. (23) found significant crude associ-
ations between serum vitamin D levels and the number 
of COVID-19 cases and mortality when they analyzed, 
in some European countries, the mean 25OHD levels re-
ported in some population studies.
Moreover, SARS-CoV-2 downregulates ACE2 expres-
sion, the main receptor for the virus to enter human cells, 
and thereby induces high angiotensin II production leading 
to myocardial and mainly lung inflammation and ARDS 
(24). In experimental models, vitamin D deficiency induces 
chronic RAS activation leading to impaired lung function 
and overexpression of profibrotic factors (13). The key 
pathogenic mechanism for SARS-CoV-2 to develop severe 
complications and lethality is the hyperinflammatory state 
(“cytokine storm”) that occurs over the first week of the 
onset of the symptoms. This cytokine storm may lead to 
severe COVID-19 complications, such as ARDS, myocar-
ditis, and acute heart and renal failure, causing increased 
mortality, especially in elderly people or in patients with 
previous cardiovascular comorbidity (25). The intrinsic 
mechanism of the anti-inflammatory effect of vitamin D 
remains uncertain, although its role on both, innate and 
adaptive immunity, has been suggested (26). In this re-
gard, experimental evidence indicates that vitamin D may 
inhibit IL-6 and tumor necrosis factor-α by attenuating 
p38 MAP kinase activation in human monocytes/macro-
phages, Moreover, 1,25OH2D
3 promotes the induction 
of T regulatory cells, thereby inhibiting production of 
proinflammatory cytokines, including IL-17, IL-21, and 
γ-interferon (27).
In this scenario, a recent study using 350  000 UK 
Biobank samples obtained between 2006 and 2010 did not 
find an association between serum 25OHD concentrations 
(or vitamin D deficiency, defined as <25 mmol/L; or insuf-
ficiency <50 mmol/L) and COVID-19 risk (assessed in 449 
Figure 1. Serum vitamin D levels in hospitalized COVID-19 patients with 
and without active oral vitamin D supplements and population-based 
controls, according to gender. Grey bars represent men and white bars 
represent women.
Figure 2. Percentage of COVID-19 cases (excluding those on vitamin D at admission) and controls according to different intervals of serum 25OHD 
levels.
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COVID-19 patients with complete data), after adjusting for 
potential confounders. Besides, their results did not support 
that vitamin D might play a role in the reported ethnic vari-
ations in COVID-19 incidence (28). Baseline 25OHD levels 
were obtained a decade ago; information on the severity 
of COVID-19 was also lacking and the study included all 
positive tests regardless of clinical outcome. D’Avolio et al. 
(29) retrospectively analyzed 107 patients who underwent 
SARS-CoV-2 polymerase chain reaction testing (80 with 
a negative and only 27 with a positive result) and simul-
taneous 25OHD measurement, in a Swiss hospital, from 
March 1 to April 14, 2020. A control cohort that included 
1377 patients with serum 25OHD levels obtained in the 
same period of the year 2019 was also analyzed. The au-
thors found that SARS-CoV-2-infected patients had median 
25OHD levels of 11.1 ng/mL, compared with 24.6 ng/mL 
in SARS-CoV-2-negative subjects and controls.
Our study was carried out in a hospitalized population, 
and, in this sense, it is worth mentioning that serum 25OHD 
has been considered as a negative acute-phase reactant, and 
its values have been reported to be decreased during acute 
inflammatory diseases (30). Thus, our COVID-19 patients 
had a high prevalence of vitamin D deficiency, and serum 
25OHD levels significantly and negatively correlated with 
ferritin and D-dimer values, indicating that vitamin D might 
have a beneficial role on the systemic inflammatory state 
of this viral disease. Interestingly, 25OHD concentrations 
in COVID-19 patients on previous hormone supplements 
were lower than expected, supporting its behavior as a nega-
tive acute-phase reactant. Therefore, 25OHD levels should 
be interpreted with caution in this scenario, although the 
population at risk for a more severe SARS-CoV-2 infection 
is probably the same as that at risk for vitamin D deficiency, 
especially elderly individuals with comorbidities.
We did not find any relationship between serum 25OHD 
levels and the parameters of COVID-19 severity, such as 
ICU admission, the need for mechanical ventilation, or 
mortality, assessed as a combined endpoint or separately. 
In contrast to other studies (31, 32), we did not find an 
association between serum 25OHD levels and the severity 
of the disease. However, it cannot be completely ruled out 
due to the small number of events and the statistical power 
of the present study. Nevertheless, we had the opportunity 
to assess a group of 19 COVID-19 patients who were on 
oral vitamin D supplements at hospital admission. We ob-
served that they had a slightly less unfavorable outcome 
than COVID-19 patients who did not take vitamin D sup-
plements, with a significantly more favorable PaO
2/FIO2 
Figure 3. Correlation between serum 25OHD and inflammatory markers (ferritin, A; D-dimer, B; and C-reactive protein, C).
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ratio, lower ferritin levels, and decreased requirements for 
tocilizumab, and even a trend for lower ICU admissions.
Interestingly enough, 6 out of 19 COVID-19 patients 
on vitamin D supplements also received chronic cortico-
steroids or immunosuppressant agents at least during the 
previous 3 months because of immune-mediated inflam-
matory diseases (IMIDs) or suprarenal insufficiency. This 
is an interesting matter of debate since it has been re-
cently suggested that the use of anticytokine and other 
immunosuppressive therapies is not associated with 
worse COVID-19 outcomes (33). In this sense, IMID 
patients on chronic corticosteroids usually received 
vitamin D supplements as prophylaxis or treatment of 
bone disease. Furthermore, they are under tight con-
trol of their comorbidities, and vitamin D deficiency is 
more frequently checked and treated than in the general 
population. Whether the outcome of COVID-19 patients 
on previous vitamin D might have been influenced by 
vitamin D status itself or by the presence of an important 
number of patients with IMIDs on corticosteroids and/or 
immunosuppressant agents is difficult to determine due 
to the size of the sample.
COVID-19 hospitalized patients had lower serum cor-
rected calcium levels than the control population. In this 
regard, Di Filippo et  al. (34) conducted a hospital-based 
retrospective study on 531 COVID-19 patients in Italy. 
Hypocalcemia, defined as serum ionized calcium level 
<1.18 mmol/L, was observed in 82% of patients, mainly 
elderly males. They also found that hypocalcemia was an 
independent predictor for hospitalization. However, and 
despite lower calcium and vitamin D levels in our COVID-
19 patients, serum parathyroid hormone was higher in 
controls. This could be related to a lower glomerular filtra-
tion rate in the control population, since there is no reason 
to suspect relative hypoparathyroidism.
Finally, it is worth mentioning that the SARS-CoV-2 
pandemic represents a challenging scenario in the manage-
ment of osteoporosis and fragility fractures. Thus, COVID-
19 hospitalized patients are mainly frail, older individuals 
with comorbidities, who are in many cases exposed to sys-
temic corticosteroids as part of the treatment of the disease 
and may require prolonged immobilization periods for a 
complete recovery. Besides, as we observed, they have a 
high percentage of vitamin D deficiency that may also con-
tribute to a loss of muscle strength and to an increase in the 
risk of falls. All these factors put these individuals at an in-
creased risk for fragility fractures (35, 36). Under these cir-
cumstances, prevention strategies should be implemented. 
According to our results, vitamin D treatment should be 
recommended in COVID-19 patients with serum 25OHD 
deficiency, since this approach might have beneficial effects 
in both the musculoskeletal and the immune system (36).
Our study has several limitations. First of all, those in-
herent to an observational study that does not permit one 
to establish whether vitamin D is simply a biomarker of ex-
posure or a biomarker of effect on the disease. Other vitamin 
D–related parameters such as the free fraction of 25OHD, 1,25 
dihydroxyvitamin D, and vitamin D binding protein were not 
measured. The number of COVID-19 patients who were on oral 
vitamin D supplements is too small and on different dosages to 
draw solid conclusions about its role in the clinical outcomes of 
the disease, although we think that it represents a unique op-
portunity to preliminary explore the differences between both 
groups of COVID-19 patients. Furthermore, the study has been 
conducted in a single Spanish tertiary care hospital, and data 
may not be generalized to other settings, ethnicities, or coun-
tries, especially those with specific policies for vitamin D sup-
plementation or food fortification. The methods to assess serum 
25OHD levels in cases and controls were different, although, 
as stated, we have found a very good correlation between both 
techniques. Finally, no dietary assessment was carried out, and 
therefore information on dietary habits is lacking.
In summary, serum 25OHD levels of hospitalized 
COVID-19 patients are lower than sex-matched population-
based controls of similar age. Men with this viral disease 
represent the group with lower serum vitamin D levels than 
women. Serum vitamin D levels below 20 ng/mL were de-
tected in 82% of COVID-19 patients, indicating that they 
represent a population with a higher risk for vitamin D de-
ficiency. In our COVID-19 patients, 25OHD was inversely 
associated with some inflammatory parameters, such as 
ferritin and D-dimer. We did not found any relationship be-
tween vitamin D concentrations or vitamin deficiency and 
the severity of the disease, including mortality, although 
further studies including a large sample size should be done 
to determine the real impact of vitamin D deficiency on the 
severity of COVID-19. Probably the best approach should 
be to identify and treat vitamin D deficiency, especially in 
high-risk individuals such as elderly people, patients with 
comorbidities, and nursing home residents, to maintain 
serum 25OHD levels above 20 ng/mL, and probably with 
a target between 30  ng/mL and 50  ng/mL. Whether the 
treatment of vitamin D deficiency will play some role in the 
prevention of the viral disease or improve the prognosis of 
patients with COVID-19 remains to be elucidated in large 
randomized controlled trials, which will be certainly neces-
sary to precisely define the role of vitamin D supplementa-
tion in futures waves of SARS-CoV-2 infection.
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